10-K: TriSalus Life Sciences Reports 2024 Results, Highlights 59% Revenue Growth

TriSalus Life Sciences reports a 59% increase in revenue for 2024, driven by its TriNav Infusion System, while continuing to develop its immunotherapeutic, nelitolimod.

Summary

• TriSalus Life Sciences, an oncology-focused medical technology company, released its 10-K filing for the year ended December 31, 2024.
• The company is focused on transforming outcomes for patients with solid tumors.
• A key strategy involves integrating innovative delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod.
• TriSalus's delivery method, Pressure-Enabled Drug Delivery (PEDD), modulates pressure and flow within blood vessels to improve therapeutic delivery into tumors.
• The TriNav Infusion System, a PEDD device, achieved $29.4 million in revenue in 2024, a 59.0% increase compared to the previous year.
• The company is also studying nelitolimod, an investigational class C TLR9 agonist, in clinical trials for uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer.
• Data from the Phase I PERIO-03 clinical trial in pancreatic cancer is expected by the end of 2025.
• TriSalus estimates a potential market opportunity of approximately $494.0 million for its TriNav device, based on current pricing and eligible patient population.
• The company is expanding its PEDD portfolio with the TriNav LV Infusion System and TriGuide Guiding Catheter.
• TriSalus projects the total addressable market for its PEDD technology in the U.S. to exceed $1.6 billion annually.
• The company has identified material weaknesses in its internal control over financial reporting and is taking steps to remediate them.
• As of December 31, 2024, TriSalus had $8.5 million in cash and cash equivalents, raising substantial doubt about its ability to continue as a going concern.
• The company expects to incur significant expenses and operating losses for the foreseeable future.
• TriSalus is exploring opportunities to partner with therapeutics companies to improve targeted delivery of therapies.
• The company is collaborating with leading cancer centers, including MD Anderson Cancer Center, to improve patient responses to CPI therapy.
• TriSalus is subject to extensive regulation by the FDA and other regulatory agencies.
• The company is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS and related agencies.
• The company is subject to healthcare fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there's strong revenue growth and promising technology, the financial instability and need for future capital raises temper the overall sentiment.

Positives

• TriNav achieved $29.4 million in revenue in 2024, representing growth of 59.0% vs. the previous year.
• The PEDD method has now been used in over 21,000 procedures, primarily TACE and TARE.
• TriNav patients showed reduced rates of post-procedure fatigue compared to non-TriNav patients.
• TriNav TACE patients had fewer 30-day inpatient visits post-procedure vs. non-TriNav patients in matched cohort comparison.
• TriNav HCC patients were more likely to have a liver transplant in matched cohort comparison.
• TriNav TARE patients with liver metastases had fewer clinical complications post-procedure vs. non-TriNav patients in matched cohort comparison.
• Effective April 1, 2025, TriNav received a second unique and permanent HCPCS code from CMS, C8004, which has been assigned to APC 5193 (Level 3 Endovascular Procedures).

Negatives

• The company has incurred significant losses since its inception, including net losses of $30.0 million and $59.4 million for the years ended December 31, 2024 and 2023, respectively.
• As of December 31, 2024, TriSalus had $8.5 million in cash and cash equivalents, raising substantial doubt about its ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting and is taking steps to remediate them.

Risks

• The company has a limited operating history and anticipates incurring increasing expenses and continuing losses for the foreseeable future.
• TriSalus's need for additional capital raises substantial doubt about its ability to continue as a going concern.
• Failure to achieve continued market acceptance of TriNav for any reason will harm the business and future prospects.
• The company is early in its pharmaceutical development efforts for nelitolimod, and its success is uncertain.
• Clinical development is a lengthy and expensive process with an uncertain outcome.
• Changes in existing third-party coverage or the inability to secure and maintain favorable reimbursement may impact the ability to sell products.
• The business and industry in which TriSalus participates are highly competitive.
• The company is subject to numerous complex regulatory requirements, and failure to comply may harm the business.
• The price of the company's securities has been and may continue to be volatile.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future as it continues to invest in the commercialization of TriNav and clinical trials for nelitolimod.

Industry Context

The announcement reflects the ongoing trends in the oncology space, with a focus on targeted drug delivery and immunotherapy. The company's PEDD technology and nelitolimod are aimed at addressing the challenges of treating solid tumors, which have historically been difficult to penetrate with systemic therapies. The increasing incidence of liver and pancreatic cancers presents a large market opportunity for companies with innovative treatment approaches.

Comparison to Industry Standards

• The 59% revenue growth reported by TriSalus is significant compared to the average growth rates in the medical device industry.
• Comparable companies in the drug delivery space, such as Medtronic and Boston Scientific, typically experience more modest growth rates.
• The company's focus on immuno-oncology and targeted drug delivery aligns with the broader industry trend towards personalized medicine.
• The company's collaboration with MD Anderson Cancer Center is a positive sign, as it demonstrates the company's commitment to working with leading academic institutions to advance its research and development efforts.
• However, the company's limited operating history and significant losses raise concerns about its long-term viability.
• Comparable companies with similar financial profiles, such as early-stage biotechnology companies, often face challenges in securing funding and achieving profitability.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity issuances.
• Employees may be affected by potential cost-cutting measures or changes in strategic direction.
• Patients could benefit from the continued development and commercialization of TriSalus's innovative technologies.
• Suppliers and creditors may be impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• The company intends to expand its commercial organization over the next several years to ensure full coverage of the embolization market and drive revenue growth.
• TriSalus will continue to progress its clinical evidence of the value of PEDD through TriSalus-sponsored and investigator-sponsored research.
• The company intends to complete these trials while also planning and initiating additional trials that have the potential to further define the benefit that TriNav can bring to areas of unmet medical need.
• The company will continue to progress our clinical evidence of the value of PEDD through TriSalus-sponsored and investigator-sponsored research.

Key Dates

Keywords

TriSalus Life Sciences, TriNav, nelitolimod, PEDD, cancer, immunotherapy, clinical trials, revenue, market opportunity, HCPCS code, financial results, risk factors, medical device, pharmaceutical, FDA